RZ-358 is a monoclonal antibody commercialized by Rezolute, with a leading Phase II program in Hypoglycemia. According to Globaldata, it is involved in 7 clinical trials, of which 5 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of RZ-358’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for RZ-358 is expected to reach an annual total of $105 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
RZ-358 Overview
RZ-358 (XOMA-358) is under development for the treatment of hyperinsulinemic hypoglycemia post gastric bypass surgery, and hypoglycemia associated with congenital hyperinsulinism. The drug candidate is a fully human monoclonal antibody which is administered through intravenous route as a solution. It is a fully human negative allosteric selective insulin receptor modulator (SIRMs) antibody derived from the XMet platform. It was also under development for the treatment of insulinomas.
Rezolute Overview
Rezolute, is a clinical-stage biopharmaceutical company that carries out the development of innovative drug therapies for the treatment of metabolic diseases related to chronic glucose imbalance. Its pipeline product portfolio includes RZ402, RZ358. RZ358 is an intravenous monoclonal antibody which is used for the treatment of conditions characterized by excessive insulin levels and is developing to treat hyperinsulinism and low blood sugar characteristic of diseases such as congenital hyperinsulinism. The company also offers RZ402 which is a potent plasma kallikrein inhibitor used for the treatment of diabetic macular edema (DME). Rezolute is headquartered in Redwood City, California, the US.
The operating loss of the company was US$43.4 million in FY2022, compared to an operating loss of US$22.4 million in FY2021. The net loss of the company was US$41.1 million in FY2022, compared to a net loss of US$20.9 million in FY2021.
For a complete picture of RZ-358’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
